Stay updated on Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization of the ClinicalTrials.gov data ingest has been postponed from June 2025 to July 2025, and the revision number has been updated from v2.16.2 to v2.16.4.
    Difference
    1.0%
    Check dated 2025-06-19T20:08:06.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:21:42.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:04:58.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page has removed an erratum related to a previously mentioned study on pembrolizumab dosing in cancer patients.
    Difference
    0.3%
    Check dated 2025-05-14T23:34:44.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:23:07.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The webpage has undergone significant content changes, including the removal of detailed study information regarding pembrolizumab (MK-3475) and its comparison to docetaxel in treating non-small cell lung cancer (NSCLC). Additionally, new identifiers and a revision number have been added.
    Difference
    24%
    Check dated 2025-04-16T11:06:32.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page.